ETOPOSIDE - Study
Preclinical
ETOPOSIDE - Study is one of 52 therapeutic programs targeting Small Cell Lung Cancer. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
141 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Tecentriq
RochePhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Vepesid
AAvyxa
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Tarlatamab-Dznl
AmgenPhase 3
Lynparza
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Medulloblastoma1 trial
A Prospective, Single-Arm, Open-Label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Arsenic Trioxide Combined With Chemotherapy in Patients With Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07856069·78 enrolled
Small Cell Lung Cancer1 trial
Explore the Relationship Between Single Nucleotide Polymorphisms and Etoposide Response and Toxicity in Patients With Small Cell Lung Cancer.
Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Preclinical·NCT01064466·600 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for ETOPOSIDE - Study. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]